IQVIA CapEx decreased by 27.0% to $127.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.6%, from $142.00M to $127.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows relatively stable performance with a -1.5% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $145.00M | $162.00M | $184.00M | $177.00M | $161.00M | $165.00M | $171.00M | $164.00M | $160.00M | $146.00M | $179.00M | $145.00M | $143.00M | $150.00M | $164.00M | $142.00M | $151.00M | $136.00M | $174.00M | $127.00M |
| QoQ Change | — | +11.7% | +13.6% | -3.8% | -9.0% | +2.5% | +3.6% | -4.1% | -2.4% | -8.8% | +22.6% | -19.0% | -1.4% | +4.9% | +9.3% | -13.4% | +6.3% | -9.9% | +27.9% | -27.0% |
| YoY Change | — | — | — | — | +11.0% | +1.9% | -7.1% | -7.3% | -0.6% | -11.5% | +4.7% | -11.6% | -10.6% | +2.7% | -8.4% | -2.1% | +5.6% | -9.3% | +6.1% | -10.6% |